The U.S. Senate Judiciary Committee approved legislation designed to reduce the success of multi-state class-action suits against drug manufacturers and other corporations by giving federal courts jurisdiction in cases that exceed $5 million and involve persons from more than one state. But the chairman of the Judiciary Committee, which sent the bill to the Senate floor on a 13-5 vote, raised questions about whether the bill would be passed in its current form.

Full Story:

Related Summaries